Composite nanoformulation therapeutics for long-term ocular delivery of macromolecules

Molecular Pharmaceutics

Volumn 13, Issue 9, 2016, Pages 2912-2922

  Agrahari, Vibhuti ^a   Agrahari, Vivek ^a   Hung, Wei Ting ^b   Christenson, Lane K ^b   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

block copolymers; controlled delivery; IgG Fab; intravitreal; macromolecule protein therapeutics; nanoparticles; ocular delivery; sustained delivery; thermosensitive gel

Indexed keywords

ACETYLSALICYLIC ACID; LACTATE DEHYDROGENASE; MACROGOL; POLYCAPROLACTONE; POLYLACTIC ACID; MACROGOL DERIVATIVE; METHOXY POLY(ETHYLENE GLYCOL-CO-EPSILON-CAPROLACTONE); NANOPARTICLE; POLY(EPSILON-CAPROLACTONE)-B-POLY(ETHYLENEGLYCOL)-B-POLY(EPSILON-CAPROLACTONE); POLYESTER; POLYLACTIDE-POLYETHYLENE GLYCOL-POLYLACTIDE; POLYMER;

AGE RELATED MACULAR DEGENERATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; CELL VIABILITY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; GEL PERMEATION CHROMATOGRAPHY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MACROMOLECULE; MOLECULAR WEIGHT; MOUSE; MTS ASSAY; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAW 264.7 CELL LINE; RETINAL PIGMENT EPITHELIUM; X RAY; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSIOLOGY; PROCEDURES; SIZE EXCLUSION CHROMATOGRAPHY; X RAY DIFFRACTION;

ANIMALS; CELL LINE; CELL SURVIVAL; CHROMATOGRAPHY, GEL; DRUG COMPOUNDING; HUMANS; INTRAVITREAL INJECTIONS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; NANOPARTICLES; POLYESTERS; POLYETHYLENE GLYCOLS; POLYMERS; RAW 264.7 CELLS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 84962108775     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00828     Document Type: Article

References (32)

1. Kaur, I. P.; Kakkar, S. Nanotherapy for posterior eye diseases J. Controlled Release 2014, 193, 100-12 10.1016/j.jconrel.2014.05.031
2. Delplace, V.; Payne, S.; Shoichet, M. Delivery strategies for treatment of age-related ocular diseases: From a biological understanding to biomaterial solutions J. Controlled Release 2015, 219, 652-68 10.1016/j.jconrel.2015.09.065
3. Ohr, M.; Kaiser, P. K. Aflibercept in wet age-related macular degeneration: a perspective review Ther. Adv. Chronic Dis. 2012, 3 (4) 153-61 10.1177/2040622312446007
4. Kovach, J. L.; Schwartz, S. G.; Flynn, H. W., Jr.; Scott, I. U. Anti-VEGF Treatment Strategies for Wet AMD J. Ophthalmol. 2012, 2012, 786870 10.1155/2012/786870
5. Campa, C.; Harding, S. P. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration Curr. Drug Targets 2011, 12 (2) 173-81 10.2174/138945011794182674
6. Stefanini, F. R.; Badaro, E.; Falabella, P.; Koss, M.; Farah, M. E.; Maia, M. Anti-VEGF for the management of diabetic macular edema J. Immunol. Res. 2014, 2014, 632307 10.1155/2014/632307
7. Avery, R. L.; Castellarin, A. A.; Steinle, N. C.; Dhoot, D. S.; Pieramici, D. J.; See, R.; Couvillion, S.; Nasir, M. A.; Rabena, M. D.; Le, K.; Maia, M.; Visich, J. E. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD Br. J. Ophthalmol. 2014, 98 (12) 1636-41 10.1136/bjophthalmol-2014-305252
8. Thakur, S. S.; Barnett, N. L.; Donaldson, M. J.; Parekh, H. S. Intravitreal drug delivery in retinal disease: are we out of our depth? Expert Opin. Drug Delivery 2014, 11 (10) 1575-90 10.1517/17425247.2014.927864
9. Schmidt-Erfurth, U.; Eldem, B.; Guymer, R.; Korobelnik, J. F.; Schlingemann, R. O.; Axer-Siegel, R.; Wiedemann, P.; Simader, C.; Gekkieva, M.; Weichselberger, A. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study Ophthalmology 2011, 118 (5) 831-9 10.1016/j.ophtha.2010.09.004
10. Malgorzata, W.; Diana, D.; Agnieszka, B.; Zofia, M. Bevacizumab intravitreal injections in the treatment of diabetic macular oedema Klinika oczna 2013, 115 (1) 15-19
11. Stewart, M. W.; Rosenfeld, P. J.; Penha, F. M.; Wang, F.; Yehoshua, Z.; Bueno-Lopez, E.; Lopez, P. F. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye) Retina 2016, 32 (3) 434-57 10.1097/IAE.0b013e31822c290f
12. Bakri, S. J.; Snyder, M. R.; Reid, J. M.; Pulido, J. S.; Singh, R. J. Pharmacokinetics of Intravitreal Bevacizumab (Avastin) Ophthalmology 2007, 114, 855 10.1016/j.ophtha.2007.01.017
13. Lowe, J.; Araujo, J.; Yang, J.; Reich, M.; Oldendorp, A.; Shiu, V.; Quarmby, V.; Lowman, H.; Lien, S.; Gaudreault, J.; Maia, M. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo Exp. Eye Res. 2007, 85 (4) 425-30 10.1016/j.exer.2007.05.008
14. Keane, P. A.; Sadda, S. R. Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians J. Ophthalmol. 2012, 2012, 483034 10.1155/2012/483034
15. Sampat, K. M.; Garg, S. J. Complications of intravitreal injections Curr. Opin Ophthalmol. 2010, 21 (3) 178-83 10.1097/ICU.0b013e328338679a
16. Pescina, S.; Sonvico, F.; Santi, P.; Nicoli, S. Therapeutics and carriers: the dual role of proteins in nanoparticles for ocular delivery Curr. Top. Med. Chem. 2015, 15 (4) 369-85 10.2174/1568026615666150108150217
17. Khurana, V.; Kwatra, D.; Agrahari, V. Recent Advances in Ocular Drug Delivery. In Advanced Drug Delivery, 1 st ed.; Mitra, A. K.; Lee, C. H.; Cheng, K., Eds.; John Wiley & Sons: Hoboken, NJ, 2014; pp 365-380.
18. Bilati, U.; Allemann, E.; Doelker, E. Poly(D,L-lactide-co-glycolide) protein-loaded nanoparticles prepared by the double emulsion method - processing and formulation issues for enhanced entrapment efficiency J. Microencapsulation 2005, 22 (2) 205-14 10.1080/02652040400026442
19. Lee, S. H.; Zhang, Z.; Feng, S. S. Nanoparticles of poly(lactide)-tocopheryl polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery Biomaterials 2007, 28 (11) 2041-50 10.1016/j.biomaterials.2007.01.003
20. Vaishya, R. D.; Mandal, A.; Gokulgandhi, M.; Patel, S.; Mitra, A. K. Reversible hydrophobic ion-paring complex strategy to minimize acylation of octreotide during long-term delivery from PLGA microparticles Int. J. Pharm. 2015, 489 (1-2) 237-45 10.1016/j.ijpharm.2015.04.075
21. Zhang, Y.; Schwendeman, S. P. Minimizing acylation of peptides in PLGA microspheres J. Controlled Release 2012, 162 (1) 119-26 10.1016/j.jconrel.2012.04.022
22. Patel, S. P.; Vaishya, R.; Mishra, G. P.; Tamboli, V.; Pal, D.; Mitra, A. K. Tailor-made pentablock copolymer based formulation for sustained ocular delivery of protein therapeutics J. Drug Delivery 2014, 2014, 401747 10.1155/2014/401747
23. Tamboli, V.; Mishra, G. P.; Mitra, A. K. Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: Effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles Colloid Polym. Sci. 2013, 291 (5) 1235-1245 10.1007/s00396-012-2854-0
24. Khurana, V.; Patel, S.; Agrahari, V.; Pal, D.; Mitra, A. Novel Pentablock Copolymer Based Nanoparticles Containing Pazopanib: A Potential Therapy for Ocular Neovascularization Recent Pat. Nanomed. 2014, 4 (1) 57-68 10.2174/1877912304999140930143244
25. Vadlapudi, A. D.; Vadlapatla, R. K.; Pal, D.; Mitra, A. K. Functional and molecular aspects of biotin uptake via SMVT in human corneal epithelial (HCEC) and retinal pigment epithelial (D407) cells AAPS J. 2012, 14 (4) 832-42 10.1208/s12248-012-9399-5
26. Khurana, V.; Vadlapudi, A. D.; Vadlapatla, R. K.; Pal, D.; Mitra, A. K. Functional characterization and molecular identification of vitamin C transporter (SVCT2) in human corneal epithelial (HCEC) and retinal pigment epithelial (D407) cells Curr. Eye Res. 2015, 40 (5) 457-69 10.3109/02713683.2014.935443
27. Youm, I.; Agrahari, V.; Murowchick, J. B.; Youan, B. B. Uptake and cytotoxicity of docetaxel-loaded hyaluronic acid-grafted oily core nanocapsules in MDA-MB 231 cancer cells Pharm. Res. 2014, 31 (9) 2439-52 10.1007/s11095-014-1339-x
28. Meng, J.; Zhang, T.; Agrahari, V.; Ezoulin, M. J.; Youan, B. B. Comparative biophysical properties of tenofovir-loaded, thiolated and nonthiolated chitosan nanoparticles intended for HIV prevention Nanomedicine 2014, 9 (11) 1595-612 10.2217/nnm.13.136
29. Filipe, V.; Hawe, A.; Jiskoot, W. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates Pharm. Res. 2010, 27 (5) 796-810 10.1007/s11095-010-0073-2
30. Costa, P.; Sousa Lobo, J. M. Modeling and comparison of dissolution profiles Eur. J. Pharm. Sci. 2001, 13 (2) 123-33 10.1016/S0928-0987(01)00095-1
31. Agrahari, V.; Zhang, C.; Zhang, T.; Li, W.; Gounev, T. K.; Oyler, N. A.; Youan, B. B. Hyaluronidase-sensitive nanoparticle templates for triggered release of HIV/AIDS microbicide in vitro AAPS J. 2014, 16 (2) 181-93 10.1208/s12248-013-9546-7
32. Lam, C. X.; Savalani, M. M.; Teoh, S. H.; Hutmacher, D. W. Dynamics of in vitro polymer degradation of polycaprolactone-based scaffolds: accelerated versus simulated physiological conditions Biomed. Mater. 2008, 3 (3) 034108 10.1088/1748-6041/3/3/034108